Related Experiment Videos
[Transcatheter hepatic arterial embolization therapy using degradable polylactic acid microspheres].
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1985
Summary
A new biodegradable microsphere therapy for hepatocellular carcinoma (HCC) shows promise. This transcatheter hepatic arterial embolization (TAE) treatment demonstrated tumor regression and an 83.3% survival rate at six months.
Area of Science:
- Oncology
- Interventional Radiology
- Biomaterials
Background:
- Transcatheter hepatic arterial embolization therapy (TAE) is a standard treatment for hepatocellular carcinoma (HCC).
- Novel drug-eluting embolic agents are needed to improve HCC treatment efficacy.
- Biodegradable materials offer potential advantages for embolic therapies.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel biodegradable microsphere embolic agent loaded with aclarubicin-HCl for treating inoperable HCC.
- To assess tumor response and survival rates in patients receiving this new therapy.
Main Methods:
- Development of biodegradable polymolecular polylactic microspheres (approx. 200 microns) loaded with aclarubicin-HCl (12% w/w).
- Administration of microspheres (50 mg aclarubicin-HCl) via transcatheter hepatic arterial embolization in 28 patients with inoperable HCC.
- Treatment involved 2-3 sessions at 2-4 week intervals.
Main Results:
- Effectiveness was indicated by decreased serum alpha-fetoprotein (AFP) levels.
- Tumor size regression was observed in treated patients.
- The accumulated survival rate at 6 months was 83.3%.
Conclusions:
- The novel biodegradable microsphere embolic agent loaded with aclarubicin-HCl is a potentially effective treatment for inoperable HCC.
- This TAE approach demonstrated promising tumor control and survival outcomes.
- Further research is warranted to explore long-term efficacy and patient selection.